Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
02 oct. 2017 16h30 HE
|
Esperion Therapeutics, Inc.
– Pivotal Phase 3 Top-Line Results for Bempedoic Acid Expected in the Second and Third Quarters of 2018 –– NDA Submission for LDL-C Lowering Indication for Bempedoic Acid Planned by First Quarter 2019...